Abciximab is the purified Fab fragment product of the chimeric monoclonal antibody 7E3, which is targeted to bind to the GPIIb/IIIa receptor of human platelets. Abciximab therefore inhibits platelet aggregation by preventing the binding of pro-coagulants such as fibrinogen, von Willebrand factor, and others to the GPIIb/IIIa receptor sites on activated platelets. Abciximab also reduces platelet adhesion to other cell types via binding to the vitronectin receptor on platelets as well as endothelial and smooth muscle cells, and via binding to the activated Mac-1 receptor on certain leukocytes (monocytes and neutrophils).
In pre-licensing clinical trials, abciximab was found to reduce death, myocardial infarctions, and urgent intervention in patients at risk of thrombosis following percutaneous transluminal coronary angioplasty or atherectomy (PTCA). It was approved as an adjunct to percutaneous coronary intervention for prevention of cardiac ischemic complications in these settings, and indications were expanded to include treatment of a broad range of patients undergoing percutaneous coronary intervention and patients with unstable angina not responding to conventional medical therapy, when percutaneous coronary intervention is planned within 24 hours.
Adverse reactions observed with abciximab therapy include bleeding and hemorrhage, thrombocytopenia, and anaphylaxis.
| Source | Link | Revision Date | Access Date |
| Reopro Prescribing Informatoin | http://www.reopro.com/index.jsp | 2005-Nov-15 | 2008-Apr-20 |
| Tcheng JE, Kandzari DE, et al; CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23 | http://circ.ahajournals.org/cgi/cont...ll/108/11/1316 | 2008-May-29 | |
| Topol, EJ, Moliterno DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001 Jun 21;344(25): 1888-94 | http://content.nejm.org/cgi/content/full/344/25/1888 | 2008-May-29 | |
| Stone GW, Grines CL, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957–66 | http://content.nejm.org/cgi/content/full/346/13/957 | 2008-May-29 | |
| Hamm CW, Heeschen C, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999 May 27;340(21):1623-9 | http://content.nejm.org/cgi/content/full/340/21/1623 | 2008-May-29 | |
| Kastrati A, Mehilli J, et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004 Jan 15;350(3):232-8 | http://content.nejm.org/cgi/content/full/350/3/232 | 2008-May-29 | |
| Neumann FJ, Kastrati A, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000 Mar 15;35(4):915-21 | http://www.ncbi.nlm.nih.gov/pubmed/10732888 | 2008-May-29 | |
| Antman EM, Gibson CM, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000 Dec;21(23):1944-53 | http://eurheartj.oxfordjournals.org/...int/21/23/1944 | 2008-May-29 | |
| Miller JM, Smalling R, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. Am J Cardiol. 1999 Oct 1;84(7):779-84 | http://www.ncbi.nlm.nih.gov/pubmed/10513773 | 2008-May-29 |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2008 Clinical Immunology Society | Web Site Disclaimer |
